company background image
EXAS logo

Exact Sciences NasdaqCM:EXAS Stock Report

Last Price

US$66.88

Market Cap

US$12.1b

7D

6.7%

1Y

-0.3%

Updated

27 Mar, 2024

Data

Company Financials +

Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$12.1b

EXAS Stock Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

EXAS fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Exact Sciences Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exact Sciences
Historical stock prices
Current Share PriceUS$66.88
52 Week HighUS$100.77
52 Week LowUS$56.05
Beta1.23
1 Month Change16.29%
3 Month Change-11.67%
1 Year Change-0.34%
3 Year Change-49.25%
5 Year Change-27.77%
Change since IPO353.42%

Recent News & Updates

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Recent updates

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Oct 31
Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans

Oct 13

Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely

Aug 15

Exact Sciences GAAP EPS of -$0.94 beats by $0.14, revenue of $521.64M beats by $25.5M

Aug 02

Exact Sciences Won't Likely Escape Consolidation In The Industry

May 25

Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation

May 14

A First Take On Exact Sciences

Feb 16

Exact Sciences Is A Pass Based On Its Intrinsic Value

Dec 10

Exact Sciences: On Point In A Bearish Market

Sep 22

Making Sense Of The Possible Merger Between Exact Sciences And Invitae

Aug 14

Shareholder Returns

EXASUS BiotechsUS Market
7D6.7%0.9%0.4%
1Y-0.3%10.3%28.8%

Return vs Industry: EXAS underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: EXAS underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is EXAS's price volatile compared to industry and market?
EXAS volatility
EXAS Average Weekly Movement6.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: EXAS has not had significant price volatility in the past 3 months.

Volatility Over Time: EXAS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19956,550Kevin Conroyhttps://www.exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Exact Sciences Corporation Fundamentals Summary

How do Exact Sciences's earnings and revenue compare to its market cap?
EXAS fundamental statistics
Market capUS$12.14b
Earnings (TTM)-US$204.15m
Revenue (TTM)US$2.50b

4.9x

P/S Ratio

-59.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EXAS income statement (TTM)
RevenueUS$2.50b
Cost of RevenueUS$654.25m
Gross ProfitUS$1.85b
Other ExpensesUS$2.05b
Earnings-US$204.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.12
Gross Margin73.83%
Net Profit Margin-8.17%
Debt/Equity Ratio75.2%

How did EXAS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.